Cargando…

Clinical efficacy of immune checkpoint inhibitors in the treatment of unresectable advanced or recurrent gastric cancer: an evidence-based review of therapies

Standard treatment options for patients with advanced gastric cancer (GC) offer limited efficacy and are associated with some toxicity, which necessitates the development of more effective therapies for improving the treatment outcomes for this disease. Immunotherapy involving immune checkpoint inhi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Togasaki, Kazuhiro, Sukawa, Yasutaka, Kanai, Takanori, Takaishi, Hiromasa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6254591/ https://www.ncbi.nlm.nih.gov/pubmed/30538493 http://dx.doi.org/10.2147/OTT.S152514

Ejemplares similares

Multiple Immune-Related Adverse Events and Anti-Tumor Efficacy: Real-World Data on Various Solid Tumors
por: Shimozaki, Keitaro, et al.
Publicado: (2020)

Inter-evaluator heterogeneity of clinical diagnosis for locally advanced esophageal squamous cell carcinoma
por: Hamamoto, Yasuo, et al.
Publicado: (2017)

Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma
por: Abd El Aziz, Mohamed A., et al.
Publicado: (2020)

Response to Immune Checkpoint Inhibitor Therapy in Patients with Unresectable Recurrent Malignant Pleural Mesothelioma Shown by FDG-PET and CT
por: Kitajima, Kazuhiro, et al.
Publicado: (2021)

Current evidence and future perspectives of immune-checkpoint inhibitors in unresectable malignant pleural mesothelioma
por: Hotta, Katsuyuki, et al.
Publicado: (2020)

Immune checkpoint inhibitors for unresectable or metastatic pleomorphic dermal sarcomas
por: Helbig, Doris, et al.
Publicado: (2022)

Efficacy and Safety Associated With Immune Checkpoint Inhibitors in Unresectable Hepatocellular Carcinoma: A Meta-analysis
por: Jácome, Alexandre A., et al.
Publicado: (2021)

A significant risk of metabolic dysfunction-associated fatty liver disease plus diabetes on subclinical atherosclerosis
por: Bessho, Rieko, et al.
Publicado: (2022)

Transarterial Chemoembolization Combined With Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Unresectable Hepatocellular Carcinoma: Efficacy and Systemic Immune Response
por: Yang, Fei, et al.
Publicado: (2022)

Early tumor cavitation with regorafenib in metastatic colorectal cancer: A case report
por: KAWASAKI, KENTA, et al.
Publicado: (2016)

Role of Immune Checkpoint Inhibitors in Advanced or Recurrent Endometrial Cancer
por: Arora, Ena, et al.
Publicado: (2018)

Immune checkpoint inhibitors in advanced and recurrent/metastatic cervical cancer
por: Han, Xiling, et al.
Publicado: (2022)

Predictors of Response and Survival in Immune Checkpoint Inhibitor-Treated Unresectable Hepatocellular Carcinoma
por: Lee, Pei-Chang, et al.
Publicado: (2020)

Fatal hemorrhage in a patient with advanced soft tissue sarcoma following radiation and pazopanib treatment: A case report
por: KAWASAKI, KENTA, et al.
Publicado: (2016)

Immune checkpoint inhibitor plus tyrosine kinase inhibitor for unresectable hepatocellular carcinoma in the real world
por: Xie, Diyang, et al.
Publicado: (2021)

Treatment features of systemic chemotherapy in young adults with unresectable advanced or recurrent gastric cancer
por: Nakayama, Izuma, et al.
Publicado: (2018)

Immune checkpoint inhibitors for treatment of advanced gastric or gastroesophageal junction cancer: Current evidence and future perspectives
por: Zhang, Zhening, et al.
Publicado: (2020)

Immune checkpoint inhibitors plus capecitabine and oxaliplatin in unresectable or advanced biliary tract cancer patients: A retrospective study
por: Zhao, Jie, et al.
Publicado: (2022)

Efficacy and safety associated with immune checkpoint inhibitors in unresectable hepatocellular carcinoma: A re‐analysis of a meta‐analysis
por: Zhou, Shouhao, et al.
Publicado: (2023)

Retrospective study of efficacy and adverse events of immune checkpoint inhibitors in 22 xeroderma pigmentosum patients with metastatic or unresectable cancers
por: Fernandez, Elvelyn R., et al.
Publicado: (2023)

Comparison of efficacy of different route of administration of chemotherapy on unresectable, advanced gastric cancer
por: Zhang, Caihua, et al.
Publicado: (2012)

Risk of HBV reactivation in patients with immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma
por: Lee, Pei-Chang, et al.
Publicado: (2020)

Histology Classification Highlights Differences in Efficacy of S-1 versus Capecitabine, in Combination with Cisplatin, for HER2-Negative Unresectable Advanced or Recurrent Gastric Cancer with Measurable Disease
por: Kawakami, Hisato, et al.
Publicado: (2022)

Safety and Efficacy of Transarterial Chemoembolization Combined with Tyrosine Kinase Inhibitor and Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma: A Single Center Experience
por: Pan, Xian, et al.
Publicado: (2023)

Checkpoint Inhibition in the Treatment of Unresectable, Advanced Lymphoepithelioma-like Hepatocellular Carcinoma
por: Hermel, David J., et al.
Publicado: (2021)

Efficacy and safety of immune checkpoint inhibitors combined anti-angiogenic therapy in patients with unresectable hepatocellular carcinoma: A meta-analysis
por: Xian, Feng, et al.
Publicado: (2022)

Clinical Efficacy and Safety of an Immune Checkpoint Inhibitor in Combination with Regorafenib Therapy as Second-Line Regimen for Patients with Unresectable Hepatocellular Carcinoma
por: Li, Jinpeng, et al.
Publicado: (2023)

A meta-analysis with systematic review: Efficacy and safety of immune checkpoint inhibitors in patients with advanced gastric cancer
por: El Helali, Aya, et al.
Publicado: (2022)

Gut microbiota and metabolites associate with outcomes of immune checkpoint inhibitor–treated unresectable hepatocellular carcinoma
por: Lee, Pei-Chang, et al.
Publicado: (2022)

Prognostic model of immune checkpoint inhibitors combined with anti-angiogenic agents in unresectable hepatocellular carcinoma
por: Li, Xiaomi, et al.
Publicado: (2022)

SUN-388 Immune Checkpoint Inhibitor Nivolumab in Advanced or Recurrent Adrenocortical Carcinoma
por: Akunjee, Munaza, et al.
Publicado: (2019)

When to apply immune checkpoint inhibitor in patients with refractory advanced gastric cancer
por: Kim, Hongsik, et al.
Publicado: (2021)

Safety and Efficacy of Transarterial Chemoembolization and Immune Checkpoint Inhibition with Camrelizumab for Treatment of Unresectable Hepatocellular Carcinoma
por: Zhang, Jin-Xing, et al.
Publicado: (2022)

Recent advances in the progress of immune checkpoint inhibitors in the treatment of advanced gastric cancer: A review
por: Shen, Jingjing, et al.
Publicado: (2022)

Efficacy of palliative radiotherapy for gastric bleeding in patients with unresectable advanced gastric cancer: a retrospective cohort study
por: Kondoh, Chihiro, et al.
Publicado: (2015)

Efficacy and safety of immune checkpoint inhibitors in patients with non‐small cell lung cancer aged 80 years or older
por: Saito, Zentaro, et al.
Publicado: (2021)

Phase I/II study of S-1 combined with paclitaxel in patients with unresectable and/or recurrent advanced gastric cancer
por: Mochiki, E, et al.
Publicado: (2006)

A Retrospective Study on Therapeutic Efficacy of Transarterial Chemoembolization Combined With Immune Checkpoint Inhibitors Plus Lenvatinib in Patients With Unresectable Hepatocellular Carcinoma
por: Teng, Ying, et al.
Publicado: (2022)

Efficacy of treatment based on TKIs in combination with PD-1 inhibitors for unresectable recurrent hepatocellular carcinoma
por: Zhang, Ze, et al.
Publicado: (2023)

Resistance to immune checkpoint inhibitors in gastric cancer
por: Liu, Kai, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_htr6l8u71940ba1lh4esv0va2g